15324 Long-term management of moderate to severe plaque psoriasis: Maintenance of treatment success following cessation of fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in patients with baseline body surface area of 6%-12%

Document Type

Conference Proceeding

Publication Date


Publication Title

J Am Acad Dermatol


Topical therapy is the mainstay of treatment for patients with localized psoriasis. The objective was to investigate maintenance of effect with halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion. In this 1-year open-label study, patients with moderate to severe psoriasis applied HP/TAZ once-daily. At week 8, HP/TAZ was stopped for treatment success (Investigator Global Assessment [IGA] score of ‘clear’ or ‘almost clear’); participants not reaching treatment success were treated for an additional 4 weeks. At week 12, any patient demonstrating ≥1-grade IGA improvement continued and was managed in 4-week cycles (no treatment success: continued HP/TAZ; achieved treatment success: no treatment until next evaluation). Maximum continuous exposure was 24 weeks. This post hoc analysis evaluated maintenance in participants with high baseline Body Surface Area (BSA) 6%-12% (n = 210). At week 8, 50% achieved, BSA ≤5%. For patients participating at least 1 year in the study, 50.0% and 21.4% maintained, BSA ≤5% and ≤3%, respectively. At time of treatment success (n = 102), BSA was ≤5%, ≤3%, ≤2%, and ≤1% in 74.5%, 59.8%, 46.1%, and 33.3% of participants, respectively. Of participants who stopped therapy after treatment success: 5.7% did not require retreatment, 12.9% did not require retreatment for ≥3 months, 21.4% did not require retreatment for ≥2 months, and 44.3% did not require retreatment for ≥1 month. HP/TAZ lotion provides rapid and sustained treatment success in patients with moderate to severe psoriasis with baseline, BSA 6%-12% when followed for 1 year, with nearly half of participants not requiring retreatment for ≥1 month.


Funding: Ortho Dermatologics.





First Page


This document is currently not available here.